Compare Cytokinetics Inc (CYTK) vs Quantum Computing Inc (QUBT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Quantum Computing Inc — how do they compare? Cytokinetics Inc trades at $62.91 (market cap $8.62B), while Quantum Computing Inc trades at $7.44 (market cap $1.69B). The key difference: Cytokinetics Inc is far larger — about 5.1× Quantum Computing Inc's market cap, and Cytokinetics Inc is trading nearer its 52-week high, Quantum Computing Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Quantum Computing Inc for 25 Days on average.
| CYTK | QUBT | |
|---|---|---|
Market Cap | $8.62B | $1.69B |
Volume | 2,594,626 | 7,991,522 |
Sector | Health | Technology |
52-Week High | $87.26 | $21.78 |
52-Week Low | $54.76 | $6.31 |
Typical Hold Time | 19 Days | 25 Days |
Enterprise Value | $8.72B | $753.24M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $62.01, up 1.46% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported Q2 2026 EPS of -$1.50, beating expectations, but maintains deeply negative profitability with a net income margin of -1,321.12% for 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy studies and presentations at major medical conferences.
Wall Street sentiment is overwhelmingly bullish with a 97.14% buy rating and a $112.60 consensus price target, signaling strong upside potential. However, high cash burn, substantial losses, and significant debt-to-asset ratio of 81.23% present substantial financial risks. Investment appeal hinges on successful commercialization of its pipeline amid intense competition.
QUBT trades at $7.45, down 2.23% on the day, amid a bearish technical signal from moving averages but with oscillators suggesting potential short-term bullish momentum. The company is in a pre-profitability growth phase, with revenue projected to jump to $10 million in 2026 from $682,000 in 2025, though net losses remain substantial. Recent news highlights the launch of the Dirac-3S quantum system and a $42.5 million backlog, indicating commercial progress but ongoing execution risks.
The investment case hinges on QUBT's ability to scale its quantum computing technology and convert its backlog into sustainable revenue, with a consensus analyst price target of $17.33 implying significant upside. Key risks include persistent cash burn, intense competition, and the speculative nature of the quantum computing sector, requiring careful risk assessment by investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Quantum Computing Inc
Quantum Computing Inc. is a company focused on providing accessible quantum computing and quantum-enhanced software solutions for complex problems. The company's technology is designed to run on both classical and quantum hardware, enabling businesses to explore the power of quantum computing today for applications in finance, drug discovery, and logistics. QUBT offers a platform that makes quantum algorithms and software available through the cloud, aiming to democratize access to this advanced computing paradigm.
Read more on QUBT →
